Group 1 - The core viewpoint of the article highlights the recent stock performance of Sangfor Biopharma, which experienced a decline of 5.02%, trading at 30.68 CNY per share with a transaction volume of 9.27 billion CNY as of 13:34 on August 6 [1] - Sangfor Biopharma is recognized as a leading biopharmaceutical company in China, focusing on the research, production, and sales of innovative drugs, with approximately 30 listed products and 31 products in development [1] - The company possesses comprehensive R&D and CDMO capabilities covering the entire lifecycle of biopharmaceuticals, with six global production bases and a CDMO capacity of 76,000 liters in 2023 [1] Group 2 - As of the 2024 annual report, Sangfor Biopharma reported total operating revenue of 9.108 billion CNY and a net profit of 2.09 billion CNY [2]
三生制药(01530)下跌5.02%，报30.68元/股